Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NoLith is a medical food developed by nephCentric for the dietary management and prevention of kidney stones (nephrolithiasis), specifically calcium oxalate, uric acid, and cystine stones. Formulated as a flavored oral drink mix (available in Berry Blend and Lemon-Lime), it provides 30 mEq of potassium citrate per scoop. The product works by alkalizing acidic urine and increasing urinary citrate levels, which helps inhibit the crystallization of stone-forming salts. It is positioned as a guideline-supported alternative to traditional potassium citrate tablets, designed to reduce gastrointestinal side effects such as reflux and esophagitis while encouraging the high fluid intake necessary for effective kidney stone management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NoLith.